Emergent Biosolutions (EBS) Getting Somewhat Positive Media Coverage, Study Finds
News articles about Emergent Biosolutions (NYSE:EBS) have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Emergent Biosolutions earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.6174823260529 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Arizona State Retirement System Has $2.75 Million Stake in Emergent Biosolutions Inc (EBS) (americanbankingnews.com)
- Emergent Biosolutions Inc (EBS) Shares Sold by Kennedy Capital Management Inc. (americanbankingnews.com)
- Emergent Biosolutions (EBS) Upgraded by ValuEngine to “Buy” (americanbankingnews.com)
- Emergent Biosolutions Inc (EBS) Shares Sold by UBS Asset Management Americas Inc. (americanbankingnews.com)
- One Gaithersburg biotech’s latest marketing push: Selling doomsday kits on Amazon – Washington Business Journal (bizjournals.com)
Emergent Biosolutions (NYSE EBS) opened at $50.95 on Thursday. The firm has a market cap of $2,500.00, a PE ratio of 31.26, a P/E/G ratio of 0.99 and a beta of 1.26. Emergent Biosolutions has a 12 month low of $27.94 and a 12 month high of $51.25. The company has a quick ratio of 3.42, a current ratio of 4.85 and a debt-to-equity ratio of 0.01.
EBS has been the topic of several analyst reports. ValuEngine raised Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Singular Research increased their price target on Emergent Biosolutions from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Chardan Capital raised their target price on Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th. Zacks Investment Research cut Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Finally, Goldman Sachs Group started coverage on Emergent Biosolutions in a research report on Wednesday, January 24th. They set a “neutral” rating and a $55.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $52.80.
In other Emergent Biosolutions news, EVP Adam Havey sold 1,898 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $49.50, for a total value of $93,951.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jerome M. Hauer sold 5,152 shares of the firm’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $50.91, for a total transaction of $262,288.32. Following the completion of the transaction, the director now directly owns 23,797 shares in the company, valued at $1,211,505.27. The disclosure for this sale can be found here. Insiders sold a total of 72,637 shares of company stock worth $3,391,674 over the last three months. Corporate insiders own 16.50% of the company’s stock.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.